Dermal fillers: a practitioner's guide to types, areas, longevity and safety

Dermal fillers are the structural workhorse of injectable aesthetics, and the term covers far more ground than most patients realise when they search for it. This guide is the overview to anchor your filler service: what dermal fillers actually are, the areas they treat, how long they last, the risks that genuinely matter, and the consent and record standard that protects both patient and practitioner. It links out to the area-specific and aftercare guides for each treatment.

What dermal fillers are

A dermal filler is an injectable gel placed into or under the skin to restore volume, smooth a line or define a feature. The large majority of fillers used in UK aesthetics are made from hyaluronic acid, a sugar that occurs naturally in skin, manufactured into a cross-linked gel. Cross-linking is what makes a filler behave structurally: rather than dispersing through the tissue, the gel holds its shape at the point of placement, which is why the result is visible immediately.

This is the clean distinction to draw at consultation. Filler adds shape. It answers “I want this area to look fuller, smoother or more defined”. It is different from skin-quality injectables like Profhilo, skin boosters and polynucleotides, which spread rather than hold and change how the skin behaves rather than how a feature is shaped. A patient who wants better skin quality and is given filler will be volumised without the result they wanted, and the reverse is equally true, so the consultation has to separate the two intentions before anything is drawn up.

A key safety feature of hyaluronic acid fillers specifically is that they are dissolvable. Hyaluronidase is an enzyme that breaks the gel down, which means an unsatisfactory result, a lump or, critically, a vascular complication can be reversed. Non-hyaluronic-acid fillers, such as those based on calcium hydroxylapatite or poly-L-lactic acid, are not reversible in the same way and carry a different risk profile.

The areas fillers treat

Filler is area-led, and each area has its own technique, product choice and risk considerations:

• Lips, for volume, hydration and shape, the most requested area; see lip filler aftercare.
• Cheeks and jawline, for midface volume and lower-face definition; covered in the cheek and jawline filler guide.
• Tear troughs, the under-eye hollow, a technically demanding area covered in the tear trough filler guide.
• Chin and jaw, for profile balance and definition.
• Nasolabial folds and marionette lines, for softening the lines from nose to mouth.
• Non-surgical rhinoplasty, reshaping the nose with small, careful placements, one of the higher-risk uses because of the vessels involved.

How long dermal fillers last

Longevity depends on the product, the area and the individual, and patients always want a single number you cannot honestly give them. The realistic framing is a range: lip filler tends toward the shorter end because the area is mobile, often six to twelve months, while denser products in less mobile areas such as the cheeks or chin can last twelve to eighteen months or more. Metabolism, the product chosen and the amount placed all move the figure. The honest message is that filler is not permanent and is maintained rather than done once.

The risks that matter

Most filler side effects are minor and expected: swelling, bruising, tenderness and small lumps that settle. Patients should be told these are normal and given written aftercare. Two issues sit in a different category and define how seriously a clinic runs its filler service.

The first is vascular occlusion: filler injected into or compressing a blood vessel, cutting off blood supply. Untreated it can cause skin necrosis and scarring, and in the highest-risk areas around the eyes, nose and forehead it can, rarely, cause permanent vision loss. It is rare but it is the emergency every injector must be trained and equipped to recognise and treat immediately, which is why access to hyaluronidase and a clear protocol is non-negotiable. Hyaluronidase is a prescription-only medicine in the UK, so a non-prescribing injector needs a named prescriber and an agreed emergency pathway in place before treating, not after a complication starts. The second is filler migration, product moving from where it was placed, most discussed in lips; our filler migration guide covers what it is and is not. Delayed complications such as nodules and infection are less common but must be documented and managed.

This risk profile is exactly why who injects, with what training, and with what records, matters, and why the area is a focus of England’s planned licensing scheme.

Consultation, consent and records

Filler is a prescription-adjacent, higher-risk treatment and the documentation should match. At consultation, assess suitability and expectations, screen contraindications with a medical history form, and photograph the area in consistent lighting. For every treatment, record written consent, the product name, batch number and expiry, the area and volume placed, the technique, and confirmation that aftercare was sent. Batch-level records are what make a product recall manageable and are part of the licensing-ready baseline in our records checklist. A signed dermal filler consent form, naming the specific risks including vascular occlusion, skin necrosis and, rarely, vision loss, covers the consent side.

Running a filler service that holds up to scrutiny

The exposure in a filler service is rarely the injecting, it is whether, two years later, you can produce the consent, the batch number and the photographs for any treatment on demand. AesthetiClinic e-signs consent before the appointment, records the batch number on every entry, stores before photographs against the record, and sends branded aftercare automatically. See the features page for how that works, our lip filler cost guide and aesthetic treatment price guide for typical UK prices, and the guides library for each treatment in detail.

This guide is general information for practitioners and patients, not medical advice. Patients should discuss suitability and risks with a qualified practitioner.